NeoGenomics, Inc. (a Nevada corporation)Underwriting Agreement • January 11th, 2021 • Neogenomics Inc • Services-testing laboratories • New York
NeoGenomics, Inc., a Nevada corporation (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofA Securities”), Morgan Stanley & Co. LLC (“Morgan Stanley”) and Goldman Sachs & Co. LLC (“Goldman Sachs”), as representatives (the “Representatives”) of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective principal amounts set forth on Schedule A hereto of $300,000,000 aggregate principal amount of the Company’s 0.25% Convertible Senior Notes due 2028 (“Initial Securities”) and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase, solely to cover over-allotments, all or any part of an additional $45,000,000 aggregate pr
NEOGENOMICS, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of January 11, 2021 0.25% Convertible Senior Notes due 2028Indenture • January 11th, 2021 • Neogenomics Inc • Services-testing laboratories • New York
INDENTURE, dated as of January 11, 2021, between NEOGENOMICS, INC., a Nevada corporation, as issuer (the “Company”, as more fully set forth in Section 1.01) and U.S. BANK NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee”, as more fully set forth in Section 1.01).
